title: Self-replicating alphavirus RNA vaccines.
abstract: Recombinant nucleic acids are considered as promising next-generation vaccines. These vaccines express the native antigen upon delivery into tissue, thus mimicking live attenuated vaccines without having the risk of reversion to pathogenicity. They also stimulate the innate immune system, thus potentiating responses. Nucleic acid vaccines are easy to produce at reasonable cost and are stable. During the past years, focus has been on the use of plasmid DNA for vaccination. Now mRNA and replicon vaccines have come into focus as promising technology platforms for vaccine development. This review discusses self-replicating RNA vaccines developed from alphavirus expression vectors. These replicon vaccines can be delivered as RNA, DNA or as recombinant virus particles. All three platforms have been pre-clinically evaluated as vaccines against a number of infectious diseases and cancer. Results have been very encouraging and propelled the first human clinical trials, the results of which have been promising.
authors.affiliation: Department of Microbiology, Tumor and Cell Biology Karolinska Institutet, Stockholm, Sweden.
authors.forename: Karl
authors.initials: K
authors.lastname: Ljungberg
authors.forename: Peter
authors.initials: P
authors.lastname: Liljeström
mesh_terms: D000524:Alphavirus / Q000276:immunology*; D002986:Clinical Trials as Topic; D004274:DNA, Recombinant; D005822:Genetic Vectors; D006801:Humans; D010957:Plasmids; D012313:RNA / Q000276:immunology*; D012093:Replicon / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA / Q000276:immunology*
chemical_list: D004274:DNA, Recombinant; D019444:Vaccines, DNA; D012313:RNA
keywords: RNA vaccine; adjuvant; alphavirus; electroporation; prime-boost; replicon; self-replicating RNA; vaccine